Format

Send to

Choose Destination
Cold Spring Harb Protoc. 2013 Nov 1;2013(11). pii: pdb.top069856. doi: 10.1101/pdb.top069856.

Accelerating cancer modeling with RNAi and nongermline genetically engineered mouse models.

Author information

1
Memorial Sloan-Kettering Cancer Center, New York, New York 10065;

Abstract

For more than two decades, genetically engineered mouse models have been key to our mechanistic understanding of tumorigenesis and cancer progression. Recently, the massive quantity of data emerging from cancer genomics studies has demanded a corresponding increase in the efficiency and throughput of in vivo models for functional testing of putative cancer genes. Already a mainstay of cancer research, recent innovations in RNA interference (RNAi) technology have extended its utility for studying gene function and genetic interactions, enabling tissue-specific, inducible and reversible gene silencing in vivo. Concurrent advances in embryonic stem cell (ESC) culture and genome engineering have accelerated several steps of genetically engineered mouse model production and have facilitated the incorporation of RNAi technology into these models. Here, we review the current state of these technologies and examine how their integration has the potential to dramatically enhance the throughput and capabilities of animal models for cancer.

PMID:
24184755
PMCID:
PMC4102000
DOI:
10.1101/pdb.top069856
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center